Literature DB >> 21620441

Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the AURICULA registry in Sweden.

Karl M Jönsson1, Mattias Wieloch, Gunnar Sterner, Ulf Nyman, Sölve Elmståhl, Gunnar Engström, Peter J Svensson.   

Abstract

INTRODUCTION: Numerous associations between chronic kidney disease (CKD) and atrial fibrillation (AF) have been reported and patients with CKD on anticoagulation therapy have an increased risk of bleeding. Currently, new anticoagulant agents are emerging in clinical practice, some of which are excreted by the kidneys. The proportion of AF patients on anticoagulant treatment with reduced renal function is, however, unknown.
MATERIALS AND METHODS: Using AURICULA, a Swedish registry for anticoagulation, estimated glomerular filtration rate (eGFR) was investigated in AF patients on warfarin treatment (n = 2,603). The study group was compared with a healthy sample from the population (n = 2,261). Two different creatinine prediction equations were used for calculating eGFR: the Lund-Malmö (LM) and MDRD Study equation.
RESULTS: The fraction of AF patients with eGFR <30 and <45 ml/min/1.73 m(2) were 8.1% and 22.9% with the LM and 4.3% and 16.3% with the MDRD equation, respectively, and significantly higher than corresponding values in the reference population. GFR decreased with increasing age, where 11.4% and 5.6% of AF patients aged ≥ 75 years had eGFR <30 ml/min/1.73 m(2) according to the LM and MDRD equations, respectively.
CONCLUSIONS: Severe renal impairment is common among AF patients on anticoagulant treatment with warfarin, especially at higher ages. Monitoring of renal function should be implemented in clinical practice for AF patients treated with new anticoagulants eliminated by the kidneys.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21620441     DOI: 10.1016/j.thromres.2011.04.022

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  [New oral anticoagulants for prophylaxis of stroke : Results of an expert conference on practical use in geriatric patients].

Authors:  Philipp Bahrmann; Fred Harms; Christian Martin Schambeck; Martin Wehling; Jürgen Flohr
Journal:  Z Gerontol Geriatr       Date:  2016-07       Impact factor: 1.281

Review 2.  [Anticoagulation in geriatric patients with atrial fibrillation : With what and for whom no more?]

Authors:  P Bahrmann; M Christ
Journal:  Herz       Date:  2018-05       Impact factor: 1.443

3.  Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant.

Authors:  Anum S Minhas; Qingmei Jiang; Xiaokui Gu; Brian Haymart; Eva Kline-Rogers; Steve Almany; Jay Kozlowski; Gregory D Krol; Scott Kaatz; James B Froehlich; Geoffrey D Barnes
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

4.  Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials.

Authors:  Munveer Thind; Wojciech Zareba; Dan Atar; Harry J G M Crijns; Jun Zhu; Hui-Nam Pak; James Reiffel; Ulf Ludwigs; Mattias Wieloch; John Stewart; Peter Kowey
Journal:  Clin Cardiol       Date:  2022-01-12       Impact factor: 2.882

5.  Non-Vitamin K Oral Anticoagulants Assessment in High Risk of Bleeding Patients with Non-Valvular Atrial Fibrillation.

Authors:  Pedro Silva Cunha; André Viveiros Monteiro; Madalena Coutinho Cruz; Paula Malveiro; João Pedro Reis; Guilherme Portugal; Ana Dias; Rui Cruz Ferreira; Mário Martins Oliveira
Journal:  Geriatrics (Basel)       Date:  2022-02-17

6.  Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Pharmaceuticals (Basel)       Date:  2012-02-03

7.  Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial.

Authors:  Mate Vamos; Jonas Oldgren; Gi-Byoung Nam; Gregory Y H Lip; Hugh Calkins; Jun Zhu; Kwo-Chang Ueng; Ulf Ludwigs; Mattias Wieloch; John Stewart; Stefan H Hohnloser
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2022-06-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.